New application of compound CDDO-Im in prevention or treatment of foot-and-mouth disease

The compound CDDO-Im reduces viral replication by inhibiting the expression of structural proteins of foot-and-mouth disease virus, thus solving the problem of the lack of effective drugs in the existing technology and achieving effective prevention and treatment of foot-and-mouth disease.

CN118903154AActive Publication Date: 2024-11-08LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Patent Information

Application Number
CN202411156906.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-08
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

There is a lack of effective drugs in the current technology for preventing or treating the replication and immunosuppression of foot-and-mouth disease virus, and vaccine prevention and control have limitations.

Method used

Using the compound CDDO-Im as an activator, the virus replication level is reduced by inhibiting the expression of foot-and-mouth disease virus structural proteins, and various pharmaceutically acceptable dosage forms are prepared for the prevention or treatment of foot-and-mouth disease.

Benefits of technology

The compound CDDO-Im can significantly inhibit the replication and structural protein expression of foot-and-mouth disease virus, specifically inhibit viral infection, and has no effect on African swine fever virus, providing an effective means of prevention and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903154A_ABST
    Figure CN118903154A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of foot-and-mouth disease treatment, and particularly relates to novel application of a compound CDDO-Im in prevention or treatment of foot-and-mouth disease. The invention accidentally discovers that the compound CDDO-Im can express structural proteins VP0, VP3 and VP1 of the foot and mouth disease virus and inhibit the replication of the foot and mouth disease virus, and has the effect of inhibiting the infection of the foot and mouth disease virus; the compound CDDO-Im has no influence on replication of African swine fever viruses, can specifically inhibit foot-and-mouth disease viruses, can be used for preparing drugs or adjuvants for resisting foot-and-mouth disease virus infection, and is used for inhibiting replication of the foot-and-mouth disease viruses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a new use of a compound CDDO-Im for preventing or treating foot-and-mouth disease. Background Art

[0002] Foot-and-mouth disease (FMD) is an acute, severe and highly contagious disease that causes even-toed ungulates such as cattle, pigs, sheep and goats. my country has classified it as a Class I animal epidemic. The pathogen of the disease is the foot-and-mouth disease virus (FMDV), which belongs to the Picornaviridae family and is a non-enveloped single-stranded positive-strand RNA virus.

[0003] There are seven different serotypes of FMDV: O, A, C, Asia1, SAT1, SAT2 and SAT3. Each serotype contains a large number of subtypes, and there is no cross-protection between different serotypes. Currently, the effective measure to prevent and control foot-and-mouth disease is vaccine. However, foot-and-mouth disease virus has severe immunosuppression and can quickly break through the host's immune system to replicate and spread efficiently. Therefore, while vaccines are being used to prevent and control foot-and-mouth disease, it is also very necessary to develop drugs for the treatment or prevention of foot-and-mouth disease virus.

[0004] The compound CDDO-Im is an activator of Nrf2 and PPAR. The present invention unexpectedly found that the compound CDDO-Im cannot inhibit the replication of African swine fever virus, but can reduce the replication level of foot-and-mouth disease virus, inhibit the expression of foot-and-mouth disease virus structural proteins, has the effect of inhibiting foot-and-mouth disease virus infection, and can be used as an inhibitor of foot-and-mouth disease virus for the prevention or treatment of foot-and-mouth disease. Summary of the invention

[0005] In view of the above technical problems, the present invention provides a new use of a compound CDDO-Im for preventing or treating foot-and-mouth disease, which specifically includes the following contents:

[0006] In a first aspect, the present invention provides a use of a compound CDDO-Im or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing foot-and-mouth disease virus infection. The structural formula of the compound CDDO-Im is shown in the following formula (I):

[0007]

[0008] Preferably, the compound CDDO-Im or a pharmaceutically acceptable salt thereof is added to a pharmaceutically acceptable carrier and / or excipient to prepare any pharmaceutically acceptable dosage form.

[0009] Preferably, the dosage forms include tablets, sprays, granules, capsules, oral solutions, injections, suspensions, and injections.

[0010] In a second aspect, the present invention provides a use of a compound CDDO-Im or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating foot-and-mouth disease virus infection, wherein the structural formula of the compound CDDO-Im is shown in the following formula (I):

[0011]

[0012] Preferably, the compound CDDO-Im or a pharmaceutically acceptable salt thereof is added to a pharmaceutically acceptable carrier and / or excipient to prepare any pharmaceutically acceptable dosage form.

[0013] Preferably, the dosage forms include tablets, sprays, granules, capsules, oral solutions, injections, suspensions, and injections.

[0014] In a third aspect, the present invention provides the use of the compound CDDO-Im in the preparation of an agent for inhibiting the expression of the structural protein VP0 of the foot-and-mouth disease virus; the structural formula of the compound CDDO-Im is shown in the following formula (I):

[0015]

[0016] In a fourth aspect, the present invention provides the use of the compound CDDO-Im in the preparation of an agent for inhibiting the expression of the structural protein VP1 of the foot-and-mouth disease virus; the structural formula of the compound CDDO-Im is shown in the following formula (I):

[0017]

[0018] In a fifth aspect, the present invention provides the use of the compound CDDO-Im in the preparation of an agent for inhibiting the expression of the structural protein VP3 of the foot-and-mouth disease virus; the structural formula of the compound CDDO-Im is shown in the following formula (I):

[0019]

[0020] The beneficial effects of the present invention are as follows: the present invention unexpectedly discovered that the compound CDDO-Im can reduce the replication level of foot-and-mouth disease virus, inhibit the expression of foot-and-mouth disease virus structural proteins, and has the effect of inhibiting foot-and-mouth disease virus infection; and the compound CDDO-Im has no effect on the replication of African swine fever virus, can specifically inhibit foot-and-mouth disease virus, and can be used to prepare drugs or adjuvants against foot-and-mouth disease virus infection, and is used to inhibit the replication of foot-and-mouth disease virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1This is the result diagram showing the inhibitory effect of compound CDDO-Im on FMDV;

[0022] Figure 2 This is a graph showing the experimental results of compound CDDO-Im inhibiting the level of FMDV structural proteins;

[0023] Figure 3 This is a graph showing the experimental results of the effect of compound CDDO-Im on the cell activity of PK-15 cells;

[0024] Figure 4 This is a graph showing the experimental results of the dose-dependency of compound CDDO-Im on the level of FMDV structural proteins;

[0025] Figure 5 This is a graph showing the effect of compound CDDO-Im on ASFV-eGFP. DETAILED DESCRIPTION

[0026] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the present invention is further described below in conjunction with specific implementation methods. However, the protection scope of the present invention is not limited to the following embodiments.

[0027] The experiments described in the following examples were performed with biosafety clearance and foot-and-mouth disease laboratory activity permit.

[0028] The structural formula of the compound CDDO-Im described in the following examples is shown in the following formula (I). The compound was purchased from Taoshu Biotechnology (TargetMol, L2510).

[0030]

[0031] Unless otherwise specified, the cells and reagents described in the following examples are commercially available.

[0032] Example 1 Preliminary screening of the effect of compound CDDO-Im on foot-and-mouth disease virus

[0033] 1. Infection and compound action

[0034] PK-15 cells were inoculated into a 12-well cell plate and cultured in a 37°C incubator for 12 hours; the compound CDDO-Im (10 mM) was diluted to 10 μM with DMEM containing 2% serum, and added to the cells together with FMDV, 500 μL each, with a total volume of 1 mL / well, and the FMDV infection dose was 1 MOI; at the same time, a 0.1% DMSO group was set as a control group and cultured in a 37°C, 5% CO2 incubator for 16-20 hours, and samples were collected when the cells showed significant lesions.

[0035] 2. Extraction of Total RNA

[0036] Discard the culture medium and extract total RNA according to the Nucleozol (MACHEREY-NAGEL) procedure. Add 400 μL of RNase-free water, vortex for 15 seconds, let stand at room temperature for 15 minutes, and centrifuge at 12,000g for 15 minutes; aspirate the supernatant into a new centrifuge tube, add isopropanol in a 1:1 ratio, mix by inversion, let stand at room temperature for 10 minutes, and centrifuge at 12,000g for 10 minutes; discard the supernatant, add 500 μL of 75% ethanol to resuspend the precipitate, centrifuge at 8,000g for 3 minutes at room temperature, discard the ethanol, and dry the precipitate; add 100-200 μL of RNase-free water to dissolve the precipitate.

[0037] 3. Reverse Transcription

[0038] An equal amount of extracted RNA was taken for reverse transcription, and the reverse transcription step was performed according to ReverTra Ace qPCR RT MasterMix with gDNARemover (Takara).

[0039] 4.qPCR

[0040] Take an equal amount of reverse transcription product for qPCR, and the qPCR enzyme is qPCR Mix (Takara), primers are 3D-F: 5'-TGGGACCATACAGGAGAAGT-3'; 3D-R: 5'-TTCACCCATCGCAGGTAAAG-3', system: 10μL Mix, 0.8μL 3D-F / R, 2μL cDNA, 6.4μL ddH2O, qPCR conditions: 95℃30s (pre-denaturation), 95℃5s and 95℃10s (40 cycles), melting curve: 95℃15s, 60℃1min, 95℃15s. Three replicate wells were made for each sample. The results were converted into the logarithm of the genomic copy number according to the standard curve.

[0041] 5. Draw the standard curve:

[0042] The standard plasmid pCDNA3.1-3D containing the FMDV 3D gene was diluted to a concentration of 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , as the template for the standard curve, perform the same qPCR as in "4", with 3 replicates for each concentration. Draw a standard curve with the logarithm of the plasmid concentration as the horizontal axis and the Ct value as the vertical axis.

[0043] The results are as follows Figure 1As shown, compound CDDO-Im has a significant inhibitory effect on the replication of FMDV in PK-15 cells.

[0044] Example 2 Immunoblotting to verify the effect of compound CDDO-Im on foot-and-mouth disease virus

[0045] The experimental method in Experiment 1 was repeated. When significant cytopathic effects appeared, the samples were collected, the supernatant was discarded, 150 μL / well RIPA (containing protease inhibitors) was added to the cells, lysed on ice for 30 min, 50 μL 4× protein loading buffer was added, vortexed to mix, 100°C for 10 min, centrifuged at 8000 rpm for 5 min, SDS-PAGE, sample volume 20 μL, 80 V for 30 min, 120 V for 60 min; transfer to membrane, 230 mA for 2 h, blocked with 5% skim milk powder for 2 h, incubated with FMDV-O polyclonal antibody (prepared and stored in this laboratory) at 4°C overnight, incubated with secondary antibody for 1 h, and exposed.

[0046] The results are as follows Figure 2 As shown, compound CDDO-Im significantly inhibited the expression levels of FMDV structural proteins VP0, VP3 and VP1.

[0047] Example 3 CCK-8 assay to detect the effect of compound CDDO-Im on the cell activity of PK-15 cells

[0048] PK-15 cells were cultured at a rate of 1×10 5 / well was inoculated into a 96-well cell plate, and after culturing in a cell culture incubator at 37°C and 5% CO2 for 12 hours, the cells were divided into a control group and an experimental group. 0.1% (v / v) dimethyl sulfoxide (DMSO) was added to the cells of the control group, and DMEM (10% FBS) culture medium containing 0.2, 0.5, 1, 2, 5, 10, and 20 μM compound CDDO-Im was added to the cells of the experimental group, and a blank group containing DMEM (10% FBS) with the same dose of DMSO as the control group was set up. The cells were placed in an incubator and cultured for 48 hours. After the culture was completed, 10 μL of CCK-8 reagent was added to each well, and the cell plate was tapped to mix the reagent and then continued to be placed in a 37°C cell culture incubator for incubation for 1 hour. After the incubation, the absorbance at 450nm was measured using an ELISA reader, and the cell activity at the corresponding compound concentration was calculated by the conversion formula [(absorbance of the experimental group - absorbance of the blank group) / (absorbance of the control group - absorbance of the blank group)]×100%=cell survival percentage.

[0049] The results are as follows Figure 3 As shown, compound CDDO-Im had no significant effect on cell viability at 0.2-10 μM.

[0050] Example 4 Dose-dependent experiment of compound CDDO-Im on the proliferation of foot-and-mouth disease virus in PK-15 cells

[0051] PK-15 was inoculated into a 12-well cell plate and cultured in a 37°C incubator for 12 h; the compound CDDO-Im (10 mM) was diluted with DMEM containing 2% serum to 0.4, 1, 2, 4, 10, and 20 μM, and added to the cells together with FMDV, 500 μL each, with a total volume of 1 mL / well, and the FMDV infection dose was 1 MOI; at the same time, a 0.1% DMSO group was set as a control group and cultured in a 37°C, 5% CO2 incubator for 16-20 hours. When the cells showed significant lesions, samples were collected for WB, and the steps were the same as in Example 2.

[0052] The results are as follows Figure 4 As shown, compound CDDO-Im inhibited the expression of structural proteins VP0, VP3 and VP1 of FMDV at 1-10 μM.

[0053] Example 5 Specificity experiment of CDDO-Im on the proliferation inhibition of foot-and-mouth disease virus in PK-15 cells

[0054] The CDDO-Im stock solution (10 mM) was diluted to 10 μM with RPMI1640 (10% FBS, 1% tertiary antibody) for later use; ASFV-eGFP fluorescent toxin was diluted 1:50 with RPMI1640 (10% FBS, 1% tertiary antibody) for later use; porcine primary alveolar macrophages (PAMs) were revived at 1×10 5 100 μL of the diluted compound CDDO-Im and 100 μL of the diluted virus solution were added to the plate and placed in a 37°C, 5% CO2 incubator for 48 hours. Three replicate wells were used for each compound, and a DMSO group was set as a control. Significant fluorescence changes in all three replicate wells indicated that the plate had an effect.

[0055] The results are as follows Figure 5 As shown, there is no significant difference in fluorescence between the compound CDDO-Im treated group and the DMSO control group, indicating that the compound CDDO-Im described in the present application has no inhibitory effect on African swine fever virus, but can specifically inhibit the replication of foot-and-mouth disease virus.

[0056] In summary, the CDDO-Im described in the present invention can inhibit the replication of FMDV in a dose-dependent manner, can specifically inhibit the replication of FMDV, and can be used as an inhibitor of foot-and-mouth disease virus for preventing or treating foot-and-mouth disease.

Claims

1. Use of the compound CDDO-Im or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing foot-and-mouth disease virus infection, wherein the structural formula of the compound CDDO-Im is shown in the following formula (I):

2. The use according to claim 1, characterized in that The compound CDDO-Im or a pharmaceutically acceptable salt thereof is added to a pharmaceutically acceptable carrier and / or excipient to prepare any pharmaceutically acceptable dosage form.

3. The use according to claim 2, characterized in that The dosage forms include tablets, sprays, granules, capsules, oral liquids, injections, suspensions, and injections.

4. Use of the compound CDDO-Im or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating foot-and-mouth disease virus infection, wherein the structural formula of the compound CDDO-Im is shown in the following formula (I):

5. The use according to claim 4, characterized in that The compound CDDO-Im or a pharmaceutically acceptable salt thereof is added to a pharmaceutically acceptable carrier and / or excipient to prepare any pharmaceutically acceptable dosage form.

6. The use according to claim 5, characterized in that The dosage forms include tablets, sprays, granules, capsules, oral liquids, injections, suspensions, and injections.

7. Use of the compound CDDO-Im in the preparation of an agent for inhibiting the expression of the structural protein VP0 of foot-and-mouth disease virus; the structural formula of the compound CDDO-Im is shown in the following formula (I):

8. Use of the compound CDDO-Im in the preparation of an agent for inhibiting the expression of the structural protein VP1 of foot-and-mouth disease virus; the structural formula of the compound CDDO-Im is shown in the following formula (I):

9. Use of the compound CDDO-Im in the preparation of an agent for inhibiting the expression of the structural protein VP3 of foot-and-mouth disease virus; the structural formula of the compound CDDO-Im is shown in the following formula (I):

Citation Information

Patent Citations

  • CDDO imidazole derivatives as well as preparation method and application thereof

    CN103897011A

  • Application of badoxolone methyl in preparation of medicine for improving viral myocarditis or viral myocardial injury

    CN116509874A

  • AGENT FOR ENHANCING EXPRESSION OF IRON METABOLISM-RELATED GENE OF MACROPHAGE CONTAINING COMPOUND HAVING Nrf2 ACTIVATION ACTION AS ACTIVE INGREDIENT

    JP2009107970A

  • Methods of treating covid-19 using bardoxolone methyl or analogs thereof

    US20230255982A1

Cited By

  • Composition for resisting foot and mouth disease virus and application

    CN121422188A